NASDAQ:VKTX Viking Therapeutics (VKTX) Stock Price, News & Analysis $25.45 -1.20 (-4.50%) As of 03:13 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Viking Therapeutics Stock (NASDAQ:VKTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Viking Therapeutics alerts:Sign Up Key Stats Today's Range$25.59▼$26.8950-Day Range$26.65▼$41.6552-Week Range$25.59▼$43.15Volume4.28 million shsAverage Volume3.20 million shsMarket Capitalization$3.21 billionP/E RatioN/ADividend YieldN/APrice Target$99.44Consensus RatingModerate Buy Company Overview Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. The company’s research programs are aimed at conditions including obesity, metabolic dysfunction-associated steatohepatitis (MASH), and other diseases involving the liver and metabolism. Viking’s leading program is VK2735, an investigational dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The company is evaluating both injectable and oral formulations of VK2735 for the treatment of obesity and related metabolic conditions. Viking is also developing VK2809, an oral thyroid hormone receptor beta agonist being studied for potential use in MASH and liver fibrosis. Founded in 2012 and headquartered in San Diego, California, Viking conducts research and clinical development activities primarily in the United States and through international clinical programs. The company is led by Brian Lian, who serves as president and chief executive officer. Viking Therapeutics trades on the Nasdaq under the symbol VKTX.AI Generated. May Contain Errors. Read More Viking Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreVKTX MarketRank™: 3.46582710219 of 5 starsViking Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 234th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingViking Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialViking Therapeutics has a consensus price target of $99.44, representing about 284.7% upside from its current price of $25.85.Amount of Analyst CoverageViking Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viking Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Viking Therapeutics are expected to grow in the coming year, from ($4.46) to ($4.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viking Therapeutics is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viking Therapeutics is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViking Therapeutics has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viking Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.73% of the float of Viking Therapeutics has been sold short.Short Interest Ratio / Days to CoverViking Therapeutics has a short interest ratio ("days to cover") of 2.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Viking Therapeutics has recently increased by 14.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViking Therapeutics does not currently pay a dividend.Dividend GrowthViking Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.35 News SentimentViking Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Viking Therapeutics this week, compared to 9 articles on an average week.Search Interest47 people have searched for VKTX on MarketBeat in the last 30 days. This is an increase of 194% compared to the previous 30 days.MarketBeat Follows32 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 433% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Viking Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,268,442.00 in company stock.Percentage Held by Insiders5.30% of the stock of Viking Therapeutics is held by insiders.Percentage Held by Institutions76.03% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Viking Therapeutics' insider trading history. Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VKTX Stock News HeadlinesViking Launches Phase 3 SUNRISE Program For Oral Obesity Drug VK27358 minutes ago | rttnews.comViking Therapeutics Starts Phase 3 Program for Oral VK2735 in Adults With Obesity8 minutes ago | finance.yahoo.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 14 at 1:00 AM | Porter & Company (Ad)Viking’s key obesity pill enters phase 3 trial – here’s what investors need to know8 minutes ago | msn.comViking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with ObesityOctober 14 at 9:30 AM | finance.yahoo.com3 Emerging Biotech Stocks With Significant Upside Potential (VKTX)Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.October 1, 2026 | marketbeat.comMarketBeat Week in Review – 09/21 - 09/25 (VKTX)A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.September 26, 2026 | marketbeat.comViking's Obesity Edge May Be Staying Power, Not Weight LossViking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.September 23, 2026 | marketbeat.comSee More Headlines VKTX Stock Analysis - Frequently Asked Questions How have VKTX shares performed this year? Viking Therapeutics' stock was trading at $35.18 on January 1st, 2026. Since then, VKTX stock has decreased by 26.5% and is now trading at $25.8520. How were Viking Therapeutics' earnings last quarter? Viking Therapeutics, Inc. (NASDAQ:VKTX) announced its earnings results on Wednesday, July, 29th. The biotechnology company reported ($1.10) EPS for the quarter, beating analysts' consensus estimates of ($1.21) by $0.11. The company's revenue for the quarter was up .0% compared to the same quarter last year. Read the conference call transcript. When did Viking Therapeutics IPO? Viking Therapeutics (VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager. Who are Viking Therapeutics' major shareholders? Viking Therapeutics' top institutional investors include Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Brian Lian, Marianna Mancini, Greg Zante, Matthew W Foehr, Lawson Macartney, Charles A Rowland Jr, J Matthew Singleton, Neil William Aubuchon and Sarah Kathryn Rouan. View institutional ownership trends. How do I buy shares of Viking Therapeutics? Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Viking Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viking Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Palantir Technologies (PLTR), Broadcom (AVGO) and NIO (NIO). Company Calendar Last Earnings7/29/2026Today10/14/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 VKTX's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VKTX CIK1607678 Webwww.vikingtherapeutics.com Phone(858) 704-4660FaxN/AEmployees65Year Founded2012Price Target and Rating Average Price Target for Viking Therapeutics$99.44 High Price Target$125.00 Low Price Target$65.00 Potential Upside/Downside+283.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($4.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$359.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-94.56% Return on Assets-82.75% Debt Debt-to-Equity RatioN/A Current Ratio4.72 Quick Ratio4.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.65 per share Price / Book4.59Miscellaneous Outstanding Shares125,990,000Free Float119,310,000Market Cap$3.27 billion OptionableOptionable Beta0.66 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:VKTX) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
